Search research articles
Contact Us
Filters
Showing results (1-10 of 13) with videos related to
Page
of 2
Sort By:
Frontiers in Cell and Developmental Biology
|
May 1, 2023
Interrogating the CD27:CD70 axis in αCD40-dependent control of pancreatic adenocarcinoma
Awndre Gamache, Claire Conarroe, Sara Adair, et al.
Clinical Lung Cancer
|
September 5, 2024
Comparative Efficacy and Safety of Lorlatinib Versus Alectinib and Lorlatinib Versus Brigatinib for ALK-Positive Advanced/Metastatic NSCLC: Matching-Adjusted Indirect Comparisons
Christine Garcia, Devin Abrahami, Anna Polli, et al.
British Journal of Haematology
|
February 8, 2017
Phase II study of bendamustine, bortezomib and dexamethasone (BBD) in the first-line treatment of patients with multiple myeloma who are not candidates for high dose chemotherapy
Jesus G Berdeja, Todd Bauer, Edward Arrowsmith, et al.
Journal of Comparative Effectiveness Research
|
December 15, 2025
Long-term efficacy and safety of lorlatinib versus alectinib in anaplastic lymphoma kinase-positive advanced/metastatic non-small cell lung cancer: matching-adjusted indirect comparison
Todd Bauer, Devin Abrahami, Anna Polli, et al.
Cancer Immunology, Immunotherapy : CII
|
May 24, 2011
Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4⁺ T cells from patients with GI malignancy
Bethany L Mundy-Bosse, Gregory S Young, Todd Bauer, et al.
Surgical Endoscopy
|
July 16, 2010
Bridge to surgery using partially covered self-expandable metal stents (PCMS) in malignant biliary stricture: an acceptable paradigm?
George H Pop, James A Richter, Bryan Sauer, et al.
BMJ Oncology
|
January 31, 2025
First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumours
Aung Naing, Kyriakos P Papadopoulos, Michael J Pishvaian, et al.
Investigational New Drugs
|
June 29, 2022
First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors
Todd Bauer, Byong Chul Cho, Rebecca Heist, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 2, 2022
Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors
Diwakar Davar, Roberta Zappasodi, Hong Wang, et al.
Future Oncology (London, England)
|
November 8, 2024
Sitravatinib in patients with solid tumors selected by molecular alterations: results from a Phase Ib study
Lyudmila Bazhenova, Dong-Wan Kim, Byoung Chul Cho, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 13) with videos related to
Sort By:
Page
of 2
Frontiers in Cell and Developmental Biology
|
May 1, 2023
Interrogating the CD27:CD70 axis in αCD40-dependent control of pancreatic adenocarcinoma
Awndre Gamache, Claire Conarroe, Sara Adair, et al.
Clinical Lung Cancer
|
September 5, 2024
Comparative Efficacy and Safety of Lorlatinib Versus Alectinib and Lorlatinib Versus Brigatinib for ALK-Positive Advanced/Metastatic NSCLC: Matching-Adjusted Indirect Comparisons
Christine Garcia, Devin Abrahami, Anna Polli, et al.
British Journal of Haematology
|
February 8, 2017
Phase II study of bendamustine, bortezomib and dexamethasone (BBD) in the first-line treatment of patients with multiple myeloma who are not candidates for high dose chemotherapy
Jesus G Berdeja, Todd Bauer, Edward Arrowsmith, et al.
Journal of Comparative Effectiveness Research
|
December 15, 2025
Long-term efficacy and safety of lorlatinib versus alectinib in anaplastic lymphoma kinase-positive advanced/metastatic non-small cell lung cancer: matching-adjusted indirect comparison
Todd Bauer, Devin Abrahami, Anna Polli, et al.
Cancer Immunology, Immunotherapy : CII
|
May 24, 2011
Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4⁺ T cells from patients with GI malignancy
Bethany L Mundy-Bosse, Gregory S Young, Todd Bauer, et al.
Surgical Endoscopy
|
July 16, 2010
Bridge to surgery using partially covered self-expandable metal stents (PCMS) in malignant biliary stricture: an acceptable paradigm?
George H Pop, James A Richter, Bryan Sauer, et al.
BMJ Oncology
|
January 31, 2025
First-in-human phase 1 study of the arginase inhibitor INCB001158 alone or combined with pembrolizumab in patients with advanced or metastatic solid tumours
Aung Naing, Kyriakos P Papadopoulos, Michael J Pishvaian, et al.
Investigational New Drugs
|
June 29, 2022
First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumors
Todd Bauer, Byong Chul Cho, Rebecca Heist, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 2, 2022
Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors
Diwakar Davar, Roberta Zappasodi, Hong Wang, et al.
Future Oncology (London, England)
|
November 8, 2024
Sitravatinib in patients with solid tumors selected by molecular alterations: results from a Phase Ib study
Lyudmila Bazhenova, Dong-Wan Kim, Byoung Chul Cho, et al.
Page
of 2